Adenocarcinoma of Lung
Conditions
Brief summary
The purpose of this study is to evaluate whether the efficacy of JNJ-757 combined with nivolumab is better than the efficacy of nivolumab monotherapy for participants with mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung. The open-label study comprises of two parts i.e. Phase 1b (safety run-in) and Phase 2. Phase1b consists of 1 arm whereas Phase 2 is randomized into 2 groups i.e. Group A and Group B.
Detailed description
This study evaluates safety and efficacy of JNJ-64041757 with nivolumab. The total study duration will be up to 3 years. It will consist of safety run-in and randomized phase which will comprise of Screening phase(Day(D) -28 to D -1),Treatment Phase,End of Adverse Event Evaluation Period (100 D after last dose of nivolumab)and Post-treatment Follow-up Phase(Every 3 Months). The primary hypothesis is that addition of JNJ-640417577 to nivolumab will result in higher objective response rate compared with nivolumab monotherapy in at least one of programmed death receptor ligand 1 subgroups in participants with relapsed or refractory StageIIIB or StageIV adenocarcinoma of lung. The study procedures include blood culture bacterial shedding assessments, pharmacokinetics, immunogenicity, and biomarkers. Safety will be monitored throughout study.
Interventions
BIOLOGICALJNJ-64041757
Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
DRUGNivolumab
Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Disease-related criteria: Histologically documented adenocarcinoma of the lung; Stage IIIB or Stage IV disease; Biopsy material available for central assessment of programmed death receptor ligand 1 (PD-L1) and mesothelin * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Progressive disease during or after platinum-based doublet chemotherapy * A woman of childbearing potential must have a negative serum or urine pregnancy test within 14 days before the first dose of nivolumab * Willing and able to adhere to the prohibitions and restrictions specified in this protocol
Exclusion criteria
* Tumor with activating epidermal growth factor receptor (EGFR) mutation or ALK translocation * More than 1 prior line of chemotherapy for metastatic disease (Phase 2) * History of disallowed therapies, as follows: In Phase 1b only: Prior exposure to anti-programmed death receptor-1(PD1), anti programmed death receptor ligand 1 (PD-L1), anti-programmed death receptor ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody within 28 days before the first dose of study agent, In Phase 2 only: Prior exposure to anti-PD1, anti PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody, History of listeriosis or vaccination with a Listeria-based vaccine or prophylactic vaccine within 28 days before the first dose of study agent, Chemotherapy within 28 days before the first dose of study agent, Radiation within 14 days before the first dose of study agent * History of any other condition that may require the initiation of anti-tumor necrosis factor alpha (TNF alpha) therapies or other immunosuppressant medications during the study * Active second malignancy within 2 years prior to Cycle 1 Day 1 (Phase 1b) or randomization (Phase 2)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Percentage of Participants With Objective Response | Up to 6.8 Months | Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Number of Participants With Anti-nivolumab Antibodies | Up to 6.8 months | Number of participants with antibodies to nivolumab were reported. |
| Phase 1b: Duration of Objective Response (DOR) | Up to 6.8 months | Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for unequivocal progression based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for unequivocal progression of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion. |
| Phase 1b: Number of Participants With Bacterial Shedding | Up to 6.8 months | Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva. |
| Phase 1b: Serum Concentrations of Nivolumab | Up to 6.8 months | Nivolumab serum concentrations were reported. |
| Phase 1b: Number of Participants With Overall Survival (OS) Event (Died) | Up to 6.8 months | Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause. |
| Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Up to 6.8 months | An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. |
| Phase 1b: Number of Participants With Positive Blood Culture | Up to 6.8 months | Number of participants with surveillance cultures positive for listeriosis were reported. |
| Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression) | Up to 6.8 months | Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for unequivocal progression based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for unequivocal progression of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion. |
Countries
Belgium, Spain, United States
Participant flow
Pre-assignment details
The trial consisted of two parts (Phase 1 b and Phase 2). However, Phase 2 was not conducted due to early termination of the study. All analyses were performed on Phase 1b data.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab Participants received nivolumab 240 milligram (mg) intravenous (IV) infusion followed by JNJ-64041757 (1\*10\^9 colony-forming units \[CFUs\]) IV infusion on Day 1 and nivolumab 240 mg IV infusion on Day 15 of each 28-day cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study. | 12 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 5 |
| Overall Study | Other | 4 |
| Overall Study | Study terminated by sponsor | 3 |
Baseline characteristics
| Characteristic | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Age, Continuous | 61.2 years STANDARD_DEVIATION 12.63 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 1 Participants |
| Race/Ethnicity, Customized White Non-Hispanic | 11 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment SPAIN | 10 Participants |
| Region of Enrollment UNITED STATES | 2 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5 / 12 |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 5 / 12 |
Outcome results
Primary
Phase 1b: Percentage of Participants With Objective Response
Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.
Time frame: Up to 6.8 Months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Percentage of Participants With Objective Response | 0 Percentage of participants |
Secondary
Phase 1b: Duration of Objective Response (DOR)
Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for unequivocal progression based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for unequivocal progression of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent. Overall number of participants analyzed is zero, since none of the participants had objective response.
Secondary
Phase 1b: Number of Participants With Anti-nivolumab Antibodies
Number of participants with antibodies to nivolumab were reported.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Anti-nivolumab Antibodies | 6 Participants |
Secondary
Phase 1b: Number of Participants With Bacterial Shedding
Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Bacterial Shedding | 0 Participants |
Secondary
Phase 1b: Number of Participants With Overall Survival (OS) Event (Died)
Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Overall Survival (OS) Event (Died) | 5 Participants |
Secondary
Phase 1b: Number of Participants With Positive Blood Culture
Number of participants with surveillance cultures positive for listeriosis were reported.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Positive Blood Culture | 1 Participants |
Secondary
Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)
Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for unequivocal progression based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for unequivocal progression of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
Time frame: Up to 6.8 months
Population: The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression) | 10 Participants |
Secondary
Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment.
Time frame: Up to 6.8 months
Population: Safety analysis set included participants who received at least 1 administration of any study medication.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 12 Participants |
Secondary
Phase 1b: Serum Concentrations of Nivolumab
Nivolumab serum concentrations were reported.
Time frame: Up to 6.8 months
Population: Pharmacokinetic (PK) population consisted of all participants who received at least 1 dose of study agent and had one PK blood sample available. Although PK samples were collected, but assays were not run due to no longer development of compound.